Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 10/20 | 0.32 |
| ▸ | CA2 | P00918 | 10/20 | 0.32 |
| ▸ | CA4 | P22748 | 10/20 | 0.32 |
| ▸ | CA9 | Q16790 | 10/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19948739 | 1.00 | CA1 (0.32) | CA1CA2CA4CA9 | |
| SCHEMBL3493185 | 0.87 | CA1 (0.32) | CA1CA2CA4CA9 | |
| SCHEMBL20746064 | 0.85 | GPR119 (0.39) | — | |
| SCHEMBL30111425 | 0.85 | NR1H2 (0.41) | — | |
| SCHEMBL4283133 | 0.84 | KDM4E (0.37) | CA1CA2CA4CA9 | |
| SCHEMBL29102553 | 0.83 | CA1 (0.40) | CA1CA2CA4CA9 | |
| SCHEMBL15770735 | 0.83 | CA1 (0.40) | CA1CA2CA4CA9 | |
| SCHEMBL29102550 | 0.83 | CA1 (0.40) | CA1CA2CA4CA9 | |
| SCHEMBL22692079 | 0.82 | PDK1 (0.33) | — | |
| SCHEMBL22692078 | 0.82 | PDK1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111989321-B | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-114269735-B | Dihydro-or tetrahydroquinazoline compound, intermediate thereof, preparation method and application | 南京创济生物医药有限公司 | 2024-02-23 | — | — | CN | disclosed |
| EP-4217071-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | Erasca, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-115803030-A | Compounds and methods for KRAS-targeted degradation | 阿维纳斯企业公司 | 2023-03-14 | — | — | CN | disclosed |
| EP-4076667-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | Erasca, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2022127827-A1 | KRASG12C PROTEIN MUTATION INHIBITOR AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | 上海维申医药有限公司 | 2022-06-23 | — | — | WO | disclosed |
| CN-114644631-A | KRAS G12C protein mutation inhibitor, preparation method thereof, pharmaceutical composition and application thereof | 上海维申医药有限公司 | 2022-06-21 | — | — | CN | disclosed |
| WO-2022087375-A1 | NOVEL HETEROCYCLIC COMPOUNDS | SPECTRUM PHARMACEUTICALS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| CN-114269735-A | Dihydro or tetrahydro quinazoline compound and intermediate, preparation method and application thereof | 南京创济生物医药有限公司 | 2022-04-01 | — | — | CN | disclosed |
| WO-2022066805-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| EP-3880208-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-09-22 | — | — | EP | disclosed |
| EP-3844151-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-07-07 | — | — | EP | disclosed |
| EP-3774777-A2 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| CN-112218859-A | Modulators of proteolysis and related methods of use | 阿尔维纳斯运营股份有限公司 | 2021-01-12 | — | — | CN | disclosed |
| EP-3710439-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| EP-3668504-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | AbbVie Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| WO-2020101736-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020047192-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-03-05 | — | — | WO | disclosed |
| WO-2019035914-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC. (US) | 2019-02-21 | — | — | WO | disclosed |